Evidence map›Paper›PMID 39140069›Full record

ArticleACS medicinal chemistry letters2024

Discovery of VU6008677: A Structurally Distinct Tricyclic M

Rory A Capstick, Sean R Bollinger, Julie L Engers, Madeline F Long, Sichen Chang, Vincent B Luscombe, Alice L Rodriguez, Colleen M Niswender, Thomas M Bridges, Olivier Boutaud and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Discovery of Pre-Clinical CandidateACS chemical neuroscience · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rory A CapstickWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Sean R BollingerWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Julie L EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Madeline F LongWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-8933-3439
Sichen ChangWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Vincent B LuscombeWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-2886-4017
Alice L RodriguezWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-5244-5103
Colleen M NiswenderWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Thomas M BridgesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
P Jeffrey ConnWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Darren W EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0003-0168-1445
Kayla J TempleWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0001-5290-574X

Funding

The Vanderbilt Specialized Chemistry Center for Accelerated Probe DevelopmentU54MH084659 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2008 to 2013
$24.1M
Vanderbilt NCDDDG for Discovery of Novel Treatments for SchizophreniaU01MH087965 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY, LINDSLEY, CRAIG · 2010 to 2014
$9.3M
NIMH NIH HHS U01 MH087965NIMH NIH HHS U54 MH084659
6 · The paper itself

Abstract

This Letter details our efforts to develop novel tricyclic muscarinic acetylcholine receptor subtype 4 (M

Identifiers

PMID39140069
PMCPMC11318023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.